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abstract
PURPOSE Thin melanomas (T1; # 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional
node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma.
However, current melanoma guidelines do not provide clear indications on when to perform SNB in T1 disease
and stress an individualized approach to SNB that considers all clinicopathologic risk factors. We aimed to
identify determinants of sentinel node (SN) status for incorporation into an externally validated nomogram to
better select patients with T1 disease for SNB.
PATIENTS AND METHODS The development cohort comprised 3,666 patients with T1 disease consecutively
treated at the Istituto Nazionale Tumori (Milan, Italy) between 2001 and 2018; 4,227 patients with T1 disease
treated at 13 other European centers over the same period formed the validation cohort. A random forest
procedure was applied to the development data set to select characteristics associated with SN status for
inclusion in a multiple binary logistic model from which a nomogram was elaborated. Decision curve analyses
assessed the clinical utility of the nomogram.
RESULTS Of patients in the development cohort, 1,635 underwent SNB; 108 patients (6.6%) were SN positive.
By univariable analysis, age, growth phase, Breslow thickness, ulceration, mitotic rate, regression, and lym-
phovascular invasion were significantly associated with SN status. The random forest procedure selected
6 variables (not growth phase) for inclusion in the logistic model and nomogram. The nomogram proved well
calibrated and had good discriminative ability in both cohorts. Decision curve analyses revealed the superior net
benefit of the nomogram compared with each individual variable included in it as well as with variables
suggested by current guidelines.
CONCLUSION We propose the nomogram as a decision aid in all patients with T1 melanoma being considered
for SNB.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Thin melanomas (T1; Breslow thickness # 1 mm) con-
stitute nearly 70% of newly diagnosed cutaneous mela-
nomas and generally have favorable prognoses,1 although
a recent study reported that 20-year melanoma-specific
survival for patients with melanoma thickness of 0.9 to
1.0 mm was as low as 71.4%.2 Thus, some patients
develop metastases, and because of the large number of
T1 cases, there is a large absolute number of recurrences.3
Sentinel node biopsy (SNB) is the standard procedure
for staging and obtaining prognostic information in
intermediate or thick melanomas,4 but for patients with
T1 disease, the probability of sentinel node (SN) in-
volvement is low (, 0.8 mm [, 5%]; 0.8-1 mm [5%-
12%])5 and SNB often constitutes overtreatment. The
eighth (2017) edition of the American Joint Com-
mittee on Cancer (AJCC) Staging Manual revised the
definitions of T1 disease: T1a is now , 0.8 mm
without ulceration, and T1b is 0.8 to 1.0 mm with
or without ulceration or , 0.8 mm with ulceration.6
These revisions prompted changes in the recommen-
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(ASCO)/Society of Surgical Oncology (SSO)7 and National
Comprehensive Cancer Network (NCCN)8 for performing
SNB—SNB is generally not recommended for T1a but can
be considered for T1b melanomas after discussion of the
potential benefits and harms with the patient.7,8 However,
2 recent reports have suggested that these recommenda-
tions carry the risk of overtreatment or undertreatment in
many patients with T1 disease.9,10
Until recently, most SN-positive patients were offered
completion lymph node dissection (CLND), because there
was evidence that it could improve prognosis.11 However,
the Multicenter Selective Lymphadenectomy Trial II
showed that immediate CLND did not improve survival.12 As
a result, the standard of care for SN-positive patients, in-
cluding those with thin melanomas, has been changing
rapidly, particularly because recent trials13,14 have sug-
gested that adjuvant therapy may become curative in the
near future.
Nevertheless, SNB remains important for prognosis and
staging.7,8 SN status identifies low- and high-risk groups,
informing decisions on follow-up frequency in low-risk and
adjuvant therapy in high-risk patients. At the same time, it is
important to avoid unnecessary SNB in view of its morbidity
and cost.
We addressed these issues by analyzing 2 large retro-
spective cohorts (development and validation cohorts) of
patients with T1 disease. We aimed to develop, externally




A total of 4,327 consecutive patients age $ 18 years di-
agnosed with T1 melanoma between 2001 and 2018 at the
Istituto Nazionale Tumori (Milan, Italy) were considered for
inclusion; 310 (7.2%) had missing data and were ex-
cluded; 351 initially treated at other hospitals with a di-
agnostic excision, found to have $ 1 risk factors, and sent
to us for definitive treatment were also excluded, because in
these cases, histologic material for reassessment was in-
completely available. Therefore, 3,666 patients formed the
development cohort (Appendix Fig A1, online only). These
patients received an initial diagnostic biopsy followed by
wide (1-cm) excision; 1,635 underwent SNB because they
were considered at high risk of occult nodal metastasis
according to then-current guidelines.11,15,16 Criteria for SNB
did not change over the study period in either the devel-
opment or validation cohort, and SNB was performed after
discussing benefits and harms with the patient and obtaining
informed consent. In the development cohort, 185 patients
eligible for SNB declined the procedure or had comorbidities
contraindicating it or were not offered it. SNB was not offered
to the remaining 1,846 patients at low risk of occult nodal
metastasis according to the guidelines.11,15,16
The following data were retrieved from the database pro-
spectively maintained by the institute: age, sex, tumor site,
deep margin status at diagnostic biopsy (clear v involved),
growth phase (radial v vertical), Breslow thickness, ulcer-
ation (present v absent), mitotic rate (mitoses per mm2),
Clark level, tumor-infiltrating lymphocytes (absent, non-
brisk, or brisk), lymphovascular invasion (presence v ab-
sence of melanoma cells in lymphatic or blood vessels),
and regression (absent, partial [, 75% of entire primary],
or extensive [$ 75%]).17 All slides were reviewed by pa-
thologists according to a common protocol,17 with diagnosis
and staging revised according to the AJCC 2017 criteria.6
The study was approved by the ethics committee of the
Istituto Nazionale Tumori.
Validation Cohort
A total of 5,188 consecutive patients age $ 18 years di-
agnosed with T1 melanoma from 2001 to 2018 were
considered; 449 (8.7%) had missing data and were ex-
cluded; 512 initially treated at other hospitals with a di-
agnostic excision were also excluded for incomplete
availability of histologic material for reassessment, leaving
4,227 to form the validation cohort (Appendix Fig A1).
These patients were treated at the Regional Cancer Center
(Stockholm, Sweden; n = 672, 15.9%); University of Leeds,
Queen Mary University of London, or Royal Marsden Na-
tional Health Service Trust (London, United Kingdom; n =
623; 14.7%); Istituto Oncologico Svizzera Italiana (Bellin-
zona, Switzerland; n = 16, 0.4%); University Hospital of
Heraklion (Heraklion, Greece; n = 346, 8.2%); and Uni-
versity Hospitals of Brescia, Florence, Genoa, Modena,
Pavia, Reggio Emilia, or Turin (Italy; n = 2,570; 60.8%).
Validation cohort patients were treated according to the
protocol applied to the development cohort. Of the 4,227
patients, 1,767 underwent SNB. Two hundred forty-nine at
high risk of SN involvement according to then-current
guidelines11,15,16 were not offered SNB or were offered it
but declined or had contraindicating comorbidities. SNB
was not offered to the other 2,211 patients, because they
were at low risk of SN involvement.11,15,16 There were too
many cases for central histopathologic revision to be fea-
sible, but all slides were reviewed at each center according
to the criteria used for the development cohort.17 Ethics
committees at all the hospitals approved the study.
Statistical Methods
The Wilcoxon-Mann-Whitney test or Fisher’s exact test was
used to assess differences in the distribution of variables
within the development cohort and between the develop-
ment and validation cohorts.
Details of the methods used to develop and test the no-
mogram to predict SN positivity are provided in the Data
Supplement (online only). Briefly, a random forest pro-
cedure18 was applied to select development cohort vari-
ables for inclusion in a multiple binary logistic model to
estimate the probability of SN positivity19; the nomogram
2 © 2020 by American Society of Clinical Oncology
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Female 778 (47.6) 852 (48.2)





, 50 796 (48.7) 838 (47.4)
$ 50 839 (51.3) 929 (52.6)
Site .0036
Head and neck 304 (18.6) 249 (14.1)
Trunk 580 (35.5) 684 (38.7)
Upper or lower limbs 751 (45.9) 834 (47.2)
Deep margin status .8257
Clear 1,517 (92.8) 1,610 (91.1)
Involved 118 (7.2) 157 (8.9)
Growth phase .7322
Radial 348 (21.3) 327 (18.5)
Vertical 1,287 (78.7) 1,440 (81.5)




$ 0.8 1,123 (68.7) 1,327 (75.1)
, 0.8 512 (31.3) 440 (24.9)
Mitoses per mm2 .7841
# 1 1,244 (76.1) 1,382 (78.2)
. 1 391 (23.9) 385 (21.8)
Ulceration .8652
Absent 1,547 (94.6) 1,687 (95.5)
Present 88 (5.4) 80 (4.5)
LVI .9463
Absent 1,614 (98.7) 1,749 (99.0)
Present 21 (1.3) 18 (1.0)
Clark level , .0001
, IV 690 (42.2) 846 (47.9)
$ IV 945 (57.8) 921 (52.1)
TILs , .0001
Absent 530 (32.4) 485 (27.4)
Nonbrisk 739 (45.2) 777 (44.0)
Brisk 366 (22.4) 505 (28.6)
(continued on following page)
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was elaborated from this model. Nomogram performance
was assessed in the development cohort by a calibration plot
as indicator of internal calibration, the Hosmer-Lemeshow
test to evaluate goodness of fit, and Harrell’s C statistic as
a measure of discriminative ability.20 Nomogram perfor-
mance was assessed in the validation cohort using the same
methods as the development cohort, overall and in each
country. The 16 patients from Bellinzona (Italian-speaking
Switzerland) were grouped with Italian patients.
Decision curve analyses were then applied to the devel-
opment cohort to assess nomogram performance in
comparison with other methods of selecting patients for
SNB.21 The analyses were performed with SAS (version
9.2)22 and R software.23
RESULTS
Characteristics of Development and Validation Cohorts
The characteristics of patients undergoing SNB in the
development and validation cohorts are listed in Table 1.
The cohorts were similar in sex ratio, age, deep margin
status, growth phase, mitotic rate, ulceration, lymphovas-
cular invasion, and SN positivity (n = 108; 6.6% v n = 94;
5.3%). Site of primary, thickness, Clark level, tumor-
infiltrating lymphocytes, regression, and number of pa-
tients undergoing CLND differed.
Median follow-up in the development cohort was
114 months (interquartile range [IQR], 90-148 months);
10-year overall survival (OS) was 89.5% (95% CI, 87.5% to
91.2%). Median follow-up in the validation cohort was
108 months (IQR, 84-139 months); 10-year OS was 90%
(95% CI, 88.1% to 92.3%).
Appendix Table A1 (online only) lists the characteristics of
development and validation cohort patients not undergoing
SNB. Sex ratio, age, deep margin status, growth phase,
thickness, ulceration, lymphovascular invasion, and tumor-
infiltrating lymphocytes were similar in the 2 cohorts.
Median follow-up in the no-SNB development cohort was
110 months (IQR, 85-138 months); 10-year OS was 97.4%
(95% CI, 95.5% to 99.4%). Median follow-up in the no-
SNB validation cohort was 106 months (IQR, 83-136
months); 10-year OS 97.8% (95% CI, 95.8% to 99.6%).
During follow-up, 16 patients (0.8%) in the no-SNB de-
velopment cohort and 17 (0.7%) in the no-SNB validation
cohort developed regional node metastases.
Table 2 summarizes univariable analyses of SN status in
relation to characteristics in development cohort patients
undergoing SNB. Young age, site of primary on head or
neck, vertical growth phase, Breslow thickness $ 0.8 mm,
mitotic rate. 1, ulceration, lymphovascular invasion, Clark
level $ IV, and extensive regression were significantly
associated with SN positivity. Univariable analyses of
SN status in relation to characteristics of validation cohort
patients undergoing SNB are summarized in Appendix
Table A2 (online only).
Factors Predicting SN Status
Random forest selection showed that 6 variables were sig-
nificant predictors of SN status (Table 3): age (P = .0092),
Breslow thickness (P = .0065), mitotic rate (P = .0038),
ulceration (P= .0054), lymphovascular invasion (P= .0089),
and regression (P = .0079).
The 6 factors found significant with the random forest
procedure were included in the binary logistic model used
to construct the nomogram; all factors were significant
predictors of SN status in the logistic model (Fig 1). No-
mogram weightings for each factor (Appendix Table A3,
online only) were derived from the b coefficients. Fac-
tors associated with SN positivity contributed points, so








Regression, % , .0001
Absent 1,203 (73.6) 1,396 (79.0)
Partial (, 75) 260 (15.9) 226 (12.8)
Extensive ($ 75) 172 (10.5) 145 (8.2)
SN status .8134
Negative 1,527 (93.4) 1,673 (94.7)
Positive 108 (6.6) 94 (5.3)
CLND .0024
Performed 93 (86.1) 76 (80.9)
Not performed 15 (13.9) 18 (19.1)
Abbreviations: CLND, completion lymph node dissection; IQR, interquartile range; LVI, lymphovascular invasion; SN, sentinel node; SNB,
sentinel node biopsy; TIL, tumor-infiltrating lymphocyte.
aWilcoxon-Mann-Whitney (age, Breslow thickness, and mitoses; all continuous) or Fisher’s exact test (other categorical variables).
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(n = 108) P a No. (%) SN Positive, %
Sex .9714
Female 727 (47.6) 51 (47.2) 778 (47.6) 6.6
Male 800 (52.4) 57 (52.8) 857 (52.4) 6.7
Age, years .0018
Median 51 47 51
Range 18-80 18-71 18-80
IQR 41-57 37-51 41-57
, 50 738 (48.3) 58 (53.7) 796 (48.7) 7.3
$ 50 789 (51.7) 50 (46.3) 839 (51.3) 6.0
Site .0034
Head and neck 279 (18.3) 25 (23.1) 304 (18.6) 8.2
Trunk 546 (35.7) 34 (31.5) 580 (35.5) 5.9
Upper or lower limbs 702 (46.0) 49 (45.4) 751 (45.9) 6.5
Deep margin status .5430
Clear 1,420 (93.0) 97 (89.8) 1,517 (92.8) 6.4
Involved 107 (7.0) 11 (10.2) 118 (7.2) 9.3
Growth phase , .0001
Radial 340 (22.3) 8 (7.4) 348 (21.3) 2.3
Vertical 1,187 (77.7) 100 (92.6) 1,287 (78.7) 7.8
Breslow thickness, mm , .0001
Median 0.8 0.9 0.8
Range 0.1-1 0.1-1 0.1-1
IQR 0.7-0.8 0.8-0.9 0.7-0.8
$ 0.8 1,034 (67.7) 89 (82.4) 1,123 (68.7) 7.9
, 0.8 493 (32.3) 19 (17.6) 512 (31.3) 3.7
Mitoses per mm2 , .0001
# 1 1,168 (76.5) 76 (70.4) 1,244 (76.1) 6.1
. 1 359 (23.5) 32 (29.6) 391 (23.9) 8.2
Ulceration , .0001
Absent 1,449 (94.9) 98 (90.7) 1,547 (94.6) 6.3
Present 78 (5.1) 10 (9.3) 88 (5.4) 11.4
LVI , .0001
Absent 1,508 (98.8) 106 (98.1) 1,614 (98.7) 6.6
Present 19 (1.2) 2 (1.9) 21 (1.3) 9.5
Clark level , .0001
, IV 651 (42.6) 39 (36.1) 690 (42.2) 5.7
$ IV 876 (57.4) 69 (63.9) 945 (57.8) 7.3
TILs .8217
Absent 496 (32.5) 34 (31.5) 530 (32.4) 6.4
Nonbrisk 691 (45.2) 48 (44.4) 739 (45.2) 6.5
Brisk 340 (22.3) 26 (24.1) 366 (22.4) 7.1
(continued on following page)
Journal of Clinical Oncology 5
Model to Predict Sentinel Node Status in Thin Melanomas
Downloaded from ascopubs.org by St. GEORGES LIBRARY, jhughes@sgul.ac.uk on March 26, 2020 from 081.147.010.093
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
increasing total points were associated with an increasingly
greater probability of a positive SN. A detailed description of
nomogram use is provided in the legend of Figure 1.
The nomogram calibration plot (Appendix Fig A2A, online
only) indicates that the nomogram was well calibrated, with
mean predicted probabilities for each subgroup close to
observed probabilities. This is further supported by a P
value of .806 for the Hosmer-Lemeshow test, indicating no
reason to reject the null hypothesis of no difference be-
tween predicted and observed SN positivity probabilities in
each subgroup.
A C index of 95.8% was obtained. This high value indicates
that the nomogram has excellent discriminative ability with
respect to the C indices of the univariable models in-
corporating each of the individual variables used to con-
struct the nomogram (mitotic rate. 1 v# 1/mm2, C index of
85.6%; presence of ulceration v absence, C index of 83.9%;
extensive regression v no regression, C index of 78.7%;
Breslow thickness $ 0.8 v , 0.8 mm, C index of 83.2%;
presence of lymphovascular invasion v absence, C index of
74.7%; and age , 50 v $ 50 years, C index of 73.1%).
The nomogramwas also well calibrated in the validation cohort
(Appendix Fig A2B), with a P value of .827 for the Hosmer-
Lemeshow test and a C index of 96.5%, again indicating
excellent discriminative ability. Similar results were obtained for
all countries assessed separately (data not shown).
The results of decision curve analyses to compare the
performance of the nomogram (nomogram model) with the
performance of univariable models representing each of
the variables selected by the random forest procedure are
shown in Figure 2. Figure 2A shows that performing an SNB
based on the indications of the nomogram has greater net
benefit than performing biopsy in all patients with at least 1
unfavorable variable as well as adhering to policies based
on each of the 6 individual variables over all threshold
probabilities. This finding is supported by the C indices of
the models of the individual variables, all of which were
lower than the C index of the nomogram. Figure 2B shows
net reduction of SNBs in relation to threshold probability
and indicates that decisions to perform SNB based on the
nomogramwould reduce the number of unnecessary SNBs
compared with decisions based on each of the 6 individual
variables.
The results of decision curve analyses to compare nomo-
gram performance (nomogrammodel) with models derived
from SNB guidelines7,8 are shown in Figure 3. For ASCO/
SSO guidelines,7 the first model was univariable with
a single dichotomous covariable to compare high-risk
(thickness$ 0.8 mm and presence of ulceration) with low-
risk patients. The second model was multivariable and
included thickness (, 0.8 v $ 0.8 mm) and ulceration
(absent v present).
For NCCN guidelines,8 we used 3 models. The first 2 were
univariable with a single dichotomous covariable to com-
pare high-risk with low-risk patients. In the first univariable









(n = 108) P a No. (%) SN Positive, %
Regression , .0001
Absent 1,126 (73.8) 77 (71.3) 1,203 (73.6) 6.4
Partial (, 75) 246 (16.1) 14 (13.0) 260 (15.9) 5.4
Extensive ($ 75) 155 (10.1) 17 (15.7) 172 (10.5) 9.9
Abbreviations: IQR, interquartile range; LVI, lymphovascular invasion; SN, sentinel node; SNB, sentinel node biopsy; TIL, tumor-infiltrating
lymphocyte.
aWilcoxon-Mann-Whitney (age, Breslow thickness, and mitoses; continuous variables) or Fisher’s exact test (other categorical variables).
TABLE 3. Results of Random Forest Variable Selection Procedure




Deep margin status .6812 .7653
Growth phase .0508 .0641
Breslow thickness .0053 .0065
Mitotic rate .0026 .0038
Ulceration .0042 .0054
LVI .0074 .0089
Clark level .0642 .0771
TILs .8125 .8917
Regression .0068 .0079
Abbreviations: FDR, false discovery rate; LVI, lymphovascular
invasion; TIL, tumor-infiltrating lymphocyte.
aPermutation test P value.
bFDR-adjusted permutation test P value.
6 © 2020 by American Society of Clinical Oncology
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model (with age; Figs 3C and 3D), high-risk patients were
those, irrespective of Breslow thickness, with at least 1 of
the following: ulceration, mitotic rate $ 2 in patients age
, 40 years, and lymphovascular invasion. In the second
univariable model (without age; Figs 3C and 3D), age was
not included (young age is not clearly defined in NCCN
guidelines). In both univariable models, the low-risk group
was composed of patients with thickness , 0.8 mm, no
ulceration, no lymphovascular invasion, and mitotic rate
, 2. The third model was multivariable and included
Breslow thickness, ulceration, mitotic rate, lymphovascular
invasion, and age. The nomogram performed better than all
guideline models both for net benefit (Figs 3A and 3C) and
reduction in SNBs (Figs 3B and 3D) at all threshold
probabilities.
DISCUSSION
Our nomogram proved well calibrated in both cohorts,
indicating excellent discriminative ability and suggesting
general applicability. Decision curve analyses showed that
the nomogram had greater net benefit and was able to
reduce the number of unnecessary SNBs compared with
use of current guidelines to select patients for SNB at all
threshold probabilities. The method used to develop the
nomogram adhered essentially to all AJCC criteria for model
acceptability, except that SNB status rather than survival
was the end point.24
In 2005, Wong et al25 published a nomogram to predict SN
status and select patients for SNB. The training set con-
sisted of 979 melanomas, 19% of which were thin. How-
ever, it examined only a limited number of clinicopathologic
characteristics and was not specifically designed for T1
melanomas.
In 2010, Faries et al26 developed a scoring system to predict
nodal recurrence by retrospective analysis of 1,732 T1
melanomas on which wide local excision alone was per-
formed. Sex, age, and Breslow thickness were included as
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FIG 1. Nomogram to predict sentinel node (SN) positivity in thin cutaneous melanoma. To estimate the probability of SN positivity for a given patient,
locate the number of mitoses per mm2 and draw a line straight up to the Points axis to determine the score associated with that number. Repeat the
process for ulceration, lymphovascular invasion, regression, age, and Breslow thickness; sum the scores and locate this sum on the Total Points axis.
Then, draw a vertical line down to the Probability axis and read off the probability.
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rate, lymphovascular invasion, and regression could not be
investigated, which may limit the generalizability of the
system.
Two recent studies9,10 indicate that performing SNB based
on T1a versus T1b status is problematic. Egger et al9
showed that not all patients with nonulcerated T1b mela-
nomas should undergo SNB, because age and mitotic rate
can identify patients with a , 5% risk of a positive SN, in
whom SNB can reasonably be omitted. Piazzalunga et al10
found that, despite a reduction in the proportion of patients
with a positive SN in the newly defined pT1a category
compared with the old pT1a, 10.71% of those with pT1a
disease had a positive SN. These studies indicate that
performing SNB based on T1a versus T1b status risks
overtreatment or undertreatment in a considerable pro-
portion of patients. The NCCN guidelines8 recommended
that SNB be considered in T1a melanomas when deep
margin status is uncertain, when mitotic rate $ 2/mm2
(particularly in young patients), or when lymphovascular
invasion is present. However, these guidelines do not
systematically consider all variables (particularly tumor
regression) that may determine whether a T1a case is likely
to be SN positive.
The current ASCO/SSO guidelines emphasize the impor-
tance of an individualized approach to SNB, suggesting
that all clinicopathologic risk factors should be assessed in
prognostic models so as to optimize risk prediction for
individual patients.7 In this context, our nomogram provides
an important additional indication as to whether SNB is
advisable.
As regards the variables included in our nomogram, all
except regression are considered to affect SN positivity in
current guidelines.7,8 However, extensive regression
emerged as an important predictor of SN positivity in our
nomogram, as indicated by the length of the axis repre-
senting this variable (Fig 1). In their retrospective analysis of
287 melanomas # 1.5 mm thick, Massi et al27 found that
only the presence of peritumoral or intratumoral in-
flammatory infiltrate and the combined variable of tumor
thickness and regression were independent predictors of
metastases; the authors suggested that regression probably
masked thickness to a greater extent in thin lesions. This
hypothesis is supported by data from the College of
American Pathologists indicating that regression . 75%
has a negative impact on prognosis.17 Nevertheless, the
findings of a review that analyzed the prognostic role of
regression were conflicting, perhaps in part because of the
use of varying criteria to define regression.28
A strength of our nomogram is that it was built from his-
topathologic variables widely used in melanoma staging. It
can therefore be used in resource-limited settings, where
clinicians and pathologists are still likely to have all the data
required to use it effectively. Another strength is that the
nomogram was validated on a large, independent, het-
erogeneous cohort of patients from wide-ranging parts of
Europe, and it is thus likely to be useful in a wide variety of
clinical settings. Furthermore, decision curve analyses
showed the nomogram had greater net benefit and was
able to reduce the number of unnecessary SNBs compared
with use of current guidelines. In view of the inability of T1a
versus T1b status to define regional node status,9,10 our
nomogram presents as an important additional source of
information to guide the decision as to whether to perform
SNB. We recommend its use in all cases where the mul-






























































FIG 2. Results of decision curve analysis. Decision curve analysis was performed to compare the policy of not performing sentinel node biopsy (SNB) for
any patient in the cohort (biopsy none) with other policies: performing SNB for all, performing SNB based on the nomogram-predicted probability, and
performing SNBbased on the probability predicted by each of the 6 univariable logisticmodels that modeled 1 of the nomogram variables. (A) Net benefit in
relation to threshold probability. (B) Net reduction of SNBs in relation to threshold probability.
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patient; if the nomogram indicates a high probability of SN
involvement, this supports proposing SNB.
A limitation of our study is that genetic signatures were not
available for much of the study period and could not be
investigated as predictors of SN status.29 If prospective
studies confirm the predictive value of genetic signatures,
they may be used in next-generation nomograms. It is also
likely that biomarkers to better select SN-positive patients
will become available in the future to improve the selection
of patients for SNB and perhaps render our nomogram
obsolete. In the meantime, we propose ongoing assess-
ment of the validity of our nomogram.
Another limitation is that 7.2% and 8.6% of patients, re-
spectively, were excluded from the development and
validation cohorts because of missing data; this is a pos-
sible source of bias. Furthermore, large proportions of the
development and validation cohorts did not undergo SNB
because of low risk, comorbidities, or refusal, and their SNB
status is unknown. Regional failure rates in these patient
cases were reassuringly low (0.8% and 0.7%, respectively),
indicating that any bias resulting from the impossibility of
including them in the analyses is likely to be negligible.
To conclude, in the context of rapidly evolving surgical and
systemic approaches to melanoma, our nomogram is able
to refine the prediction of SN status in T1 melanomas and
indicates more accurately than current guidelines whether
SNB should be performed. We recommend its use in all
patient cases where SNB is being considered.
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FIG 3. Results of decision curve analysis. Decision curve analysis was performed to compare the policy of not performing sentinel node biopsy (SNB;
biopsy none) with other policies: performing SNB for all, performing SNB based on nomogram-predicted probability, and performing SNB based on
probabilities of SNB involvement predicted by univariable and multivariable logistic models based on American Society of Clinical Oncology (ASCO)/
Society of Surgical Oncology (SSO) and National Comprehensive Cancer Network (NCCN) guidelines.7,8 (A, C) Net benefit in relation to threshold
probability. (B, D) Net reduction of SNBs in relation to threshold probability.
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FIG A1. CONSORT diagram showing (A) development and (B) validation cohort (2001-2018) patients considered, eliminated, and selected for
inclusion in the study.
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FIG A2. Nomogram-predicted probabilities were stratified into subgroups as described in the text. For each subgroup, the probability (observed proportion of
sentinel node–positive patient cases/total patient cases in each subgroup) was plotted (y-axis) against the average predicted probability (x-axis). The error
bars are Clopper-Pearson 95% CIs. The solid diagonal line is the reference line, indicating the probability of an ideal nomogram.
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TABLE A1. Clinicopathologic Characteristics of Development and Validation Cohort









Female 959 (47.2) 1,181 (48.0)





, 50 967 (47.6) 1,141 (46.4)
$ 50 1,064 (52.4) 1,319 (53.6)
Site .0018
Head and neck 299 (14.7) 275 (11.2)
Trunk 881 (43.4) 1,033 (42.0)
Upper or lower limbs 851 (41.9) 1,152 (46.8)
Deep margin status .9215
Clear 1,964 (96.7) 2,362 (96.0)
Involved 67 (3.3) 98 (4.0)
Growth phase .7931
Radial 784 (38.6) 893 (36.3)
Vertical 1,247 (61.4) 1,567 (63.7)




, 0.8 1,867 (91.9) 2,273 (92.4)
$ 0.8 164 (8.1) 187 (7.6)
Mitoses per mm2 .0042
# 1 1,824 (89.8) 2,320 (94.3)
. 1 207 (10.2) 140 (5.7)
Ulceration .9246
Absent 2,007 (98.8) 2,440 (99.2)
Present 24 (1.2) 20 (0.8)
LVI .9548
Absent 2,021 (99.5) 2,453 (99.7)
Present 10 (0.5) 7 (0.3)
Clark level .0038
, IV 1,765 (86.9) 2,253 (91.6)
$ IV 266 (13.1) 207 (8.4)
TILs .7639
Absent 1,505 (74.1) 1,887 (76.7)
Nonbrisk 414 (20.4) 455 (18.5)
Brisk 112 (5.5) 118 (4.8)
(continued on following page)
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TABLE A1. Clinicopathologic Characteristics of Development and Validation Cohort









Absent 1,708 (84.1) 2,207 (89.7)
Partial (, 75) 272 (13.4) 224 (9.1)
Extensive ($ 75) 51 (2.5) 29 (1.2)
Abbreviations: IQR, interquartile range; LVI, lymphovascular invasion; SNB,
sentinel node biopsy; TIL, tumor-infiltrating lymphocyte.
aWilcoxon-Mann-Whitney (age, Breslow thickness, and mitoses; all continuous)
or Fisher’s exact test (other categorical variables).
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(n = 94) P a No. (%) SN Positive, %
Sex .8163
Female 808 (48.3) 44 (46.8) 852 (48.2) 5.2
Male 865 (51.7) 50 (53.2) 915 (51.8) 5.5
Age, years .0134
Median 53 49 53
Range 18-81 18-73 18-81
IQR 43-59 39-54 43-59
, 50 789 (47.2) 49 (52.1) 838 (47.4) 5.8
$ 50 884 (52.8) 45 (47.9) 929 (52.6) 4.8
Site , .0001
Head and neck 230 (13.8) 19 (20.2) 249 (14.1) 7.6
Trunk 651 (38.9) 33 (35.1) 684 (38.7) 4.8
Upper or lower limbs 792 (47.3) 42 (44.7) 834 (47.2) 5.0
Deep margin status .8478
Clear 1,525 (91.2) 85 (90.4) 1,610 (91.1) 5.3
Involved 148 (8.8) 9 (9.6) 157 (8.9) 5.7
Growth phase , .0001
Radial 321 (19.2) 6 (6.4) 327 (18.5) 1.8
Vertical 1,352 (80.8) 88 (93.6) 1,440 (81.5) 6.1
Breslow thickness, mm , .0001
Median 0.9 1.0 0.9
Range 0.1-1 0.1-1 0.1-1
IQR 0.8-0.9 0.9-1.0 0.8-0.9
$ 0.8 1,246 (74.5) 81 (86.2) 1,327 (75.1) 6.1
, 0.8 427 (25.5) 13 (13.8) 440 (24.9) 3.0
Mitoses per mm2 , .0001
# 1 1,314 (78.5) 68 (72.3) 1,382 (78.2) 4.9
. 1 359 (21.5) 26 (27.7) 385 (21.8) 6.8
Ulceration , .0001
Absent 1,601 (95.7) 86 (91.5) 1,687 (95.5) 5.1
Present 72 (4.3) 8 (8.5) 80 (4.5) 10.0
LVI , .0001
Absent 1,657 (99.0) 92 (97.9) 1,749 (99.0) 5.3
Present 16 (1.0) 2 (2.1) 18 (1.0) 11.1
Clark level , .0001
, IV 810 (48.4) 36 (38.3) 846 (47.9) 4.3
$ IV 863 (51.6) 58 (61.7) 921 (52.1) 6.3
TILs .7147
Absent 461 (27.6) 24 (25.5) 485 (27.4) 4.9
Nonbrisk 737 (44.0) 40 (42.6) 777 (44.0) 5.1
Brisk 475 (28.4) 30 (31.9) 505 (28.6) 5.9
(continued on following page)
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(n = 94) P a No. (%) SN Positive, %
Regression , .0001
Absent 1,324 (79.1) 72 (76.6) 1,396 (79.0) 5.2
Partial (, 75) 217 (13.0) 9 (9.6) 226 (12.8) 4.0
Extensive ($ 75) 132 (7.9) 13 (13.8) 145 (8.2) 9.0
Abbreviations: IQR, interquartile range; LVI, lymphovascular invasion; SN, sentinel node; SNB, sentinel node biopsy; TIL, tumor-infiltrating
lymphocyte.
aWilcoxon-Mann-Whitney (age, Breslow thickness, and mitoses; continuous variables) or Fisher’s exact test (other categorical variables).
TABLE A3. Results of Multiple Binary Logistic Model to Predict SN Positivity in Development Cohort
Variable OR (b coefficient) 95% CI P
Age (, 50 v $ 50 years) 1.96 (0.673) 0.84 to 3.22 .0632
Breslow thickness ($ 0.8 v , 0.8 mm) 3.68 (1.303) 2.41 to 5.48 , .0001
Mitotic rate (. 1v # 1/mm2) 3.95 (1.374) 2.64 to 5.97 , .0001
Ulceration (present v absent) 3.83 (1.343) 2.56 to 5.62 , .0001
Regression
Partial (, 75) v absent 1.34 (0.293) 0.52 to 3.16 .0968
Extensive ($ 75) v absent 3.28 (1.188) 2.02 to 4.64 .0003
LVI (present v absent) 2.84 (1.044) 1.56 to 4.58 .0134
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: LVI, lymphovascular invasion; OR, odds ratio; SN, sentinel node.
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